Effect of Preoperative Administration of Dutasteride on Reducing Blood Loss in Perioperative Period of Transurethral Resection of Prostate
DOI:
https://doi.org/10.59058/jaimc.v21i4.202Keywords:
Benign Prostatic Hyperplasia (BPH). Transurethral resection of Prostate (TURP), 5 Alpha Reductase Inhibitor (5-ARI)Abstract
Background and Objective: Clinical benign prostatic hyperplasia (BPH), a condition that commonly occurs in aging men. It is characterized by the development of lower urinary tract symptoms (LUTS), which can lead to impairment of bladder function and potential renal complications. TURP is the gold standard surgical treatment of BPH. Dutasteride is a 5-reductase and is used for medical management. This study was planned to ascertain the effect of pre-treatment dutasteride in reducing blood loss in patients undergoing transurethral resection of prostate (TURP).
Methods: It was a randomized clinical trial carried out at Department of Urology, Jinnah Hospital Lahore in which the total study sample was divided in two groups. One group received dutasteride and the second group was the control group. The study variables were Haemoglobin and Hematocrit values, clotting profile PT and INR, serum Ca levels and uric acid, BMI, prostate volume, residual volume of urine and hospital stay. Results were presented as mean ± SD or frequency (%). The main study outcome variable was mean blood loss (calculated by change in hemoglobin and hematocrit level).
Results: 6 (10.3 %) patients needed blood transfusion in dutasteride group and 7 (12 %) in control group (p=0.14). Post-surgery change in haemoglobin and HCT levels were less in dutasteride groups as compared to the control group (ΔHb 1.94±1.27 g/dL vs. 2.16±0.73 g/dL, respectively, p=0.02; ΔHct 5.68 % ± 2.56% vs. 6.52 % ± 2.39 %, respectively, p = 0.04).
Conclusion: The present research suggests that administering Dutasteride four weeks prior to the TURPprocedure results in a decrease in blood loss during the peri-operative period, ultimately leading to improved patient outcomes.
Key words: Benign Prostatic Hyperplasia (BPH). Transurethral resection of Prostate (TURP), 5 Alpha Reductase Inhibitor (5-ARI)
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Shabbir Chaudhry, Dr.Salman Arshad, Dr. Shah Jahan Ur Rehman, Dr.Shoaib Javaid, Dr.Ismat Ullah, DR.AROOJ AHMAD
This work is licensed under a Creative Commons Attribution 4.0 International License.
The articles published in this journal come under creative commons licence Attribution 4.0 International (CC BY 4.0) which allows to copy and redistribute the material in any medium or format Adapt — remix, transform, and build upon the material for any purpose, even commercially under following terms.
-
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
The editorial board of the Journal strives hard for the authenticity and accuracy of the material published in the Journal. However, findings and statements are views of the authors and do not necessarily represent views of the Editorial Board. Many software like (Google Maps, Google Earth, Biorender (free version)) restricts the free distribution of materials prepared using these softwares. Therefore, authors are strongly advised to check the license/copyright information of the software used to prepare maps/images. In case of publication of copyright material, the correction will be published in one of the subsequent issues of the Journal, and the authors will bear the printing cost.
